Researchers have found a new line of approach for combination treatment against aggressive skin cancers.

p53, MDM4 and the formation of cancer
Chris Marine and his team has a long standing interest in p53 - a master tumor suppressor protein (in other words a protein that counteract the formation of cancer). Mutations in the p53 gene are very common in many various types of cancer. Surprisingly, mutations in p53 are (almost) never seen in melanomas. Scientists suspected that melanomas had found an alternative way of bypassing the action of p53.
The protein MDM4 has a negative effect on the action of p53 and has been the scientific focus of the VIB investigators for many years. Agnieszka Gembarska and Chris Marine have now demonstrated that (65% of) melanomas contain much higher concentrations of the MDM4 protein than normal cells. The scientists found a pharmacological way to inhibit the interaction between MDM4 and p53 and were thereby able to restore the tumor suppressive effect of p53 in melanoma cells.
Chris Marine: "The restoration of the p53 activity in the melanoma cells makes these cells more susceptible to chemotherapy and the BRAF inhibitors. In our research, we were able to identify MDM4 as a very promising target for treatment of melanoma, as part of a combination therapy.
Source-Eurekalert